Login



Forget your password?

Standard Medicare Part D

Approximately 24% of dialysis patients have Standard Medicare Part D.
Renvela® (sevelamer carbonate) is covered as a preferred medication on all national Medicare Part D plans.1

Benefits:

  • Patients pay an average co-pay of less than $35 per fill for Renvela® prior to reaching the coverage gap or "donut hole."
  • Some patients may qualify for Low-Income Subsidy (Extra Help), which provides up to $4000 a year to help pay out-of-pocket expenses.2
  • Some patients may qualify for the Renvela Medicare Part D Assistance Program (PDAP), which provides Renvela® at no cost to patients for the remainder of the calendar year.

How can you help these patients?

How can Renassist help?

  • Verify prescription drug benefits.
  • Provide information about Extra Help and PDAP.
  • Provide Medicare Part D education and support.

Indication
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information
  • Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please click here for full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

Indication
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are used to control phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information
  • Do not use sevelamer if you have a history of bowel obstruction.
  • Talk to your doctor if you have had difficulty swallowing or swallowing disorders; or if you have had digestive tract surgery or other digestive disorders, including severe constipation.
  • The most common side effects with sevelamer include vomiting, nausea, diarrhea, upset stomach, abdominal pain, flatulence, and constipation.
  • Cases of itching, rash, fecal impaction and, less commonly, slow bowel activity, bowel obstruction, and bowel perforation have been reported.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Talk to your doctor if you have difficulty swallowing medicines in tablet form. Renvela powder for oral suspension may be considered by your doctor if you have a history of difficulty swallowing.
  • Your doctor should monitor bicarbonate and chloride blood levels.
  • Reduced vitamins D, E, and K (clotting factors) and folic acid blood levels may be followed by your doctor.
  • Talk to your doctor when taking sevelamer with other medications.
  • Promptly contact your doctor if you experience severe abdominal pain, new or worsening constipation, or other severe intestinal symptoms while on sevelamer.
  • Take sevelamer with meals and adhere to your prescribed diet.

Please click here for full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

References
1. Data on file, Sanofi US. August 2016.
2. US Social Security Administration. Apply online for Extra Help with Medicare prescription drug costs: www.ssa.gov/pubs/EN-05-10525.pdf. Published April 2016. Accessed December 2016.

    Terms and conditions  |  Privacy policy  |  Prescribing Information for Renvela®  |  Prescribing Information for Renagel®  |  Contact Renassist  |  Resources